HC Wainwright & Co. Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has upgraded Oncternal Therapeutics (NASDAQ:ONCT) from Neutral to Buy and set a price target of $2.
September 18, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncternal Therapeutics has been upgraded from Neutral to Buy by HC Wainwright & Co. with a new price target of $2.
The upgrade from Neutral to Buy by a reputable analyst indicates a positive outlook for Oncternal Therapeutics. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100